HIV/AIDS

Focusing on the importance of rapid treatment initiation in HIV, Shauna Applin, ARNP, reviews available therapies and provides clinical insights on treatment considerations.

Shauna Applin, ARNP, provides an overview of the therapeutic algorithm for patients with HIV, highlighting treatment guidelines and currently available therapies.

A panel of experts on HIV discuss decision-making practices for patients who have suboptimal response to their current treatment regimen.

Focusing on the management of patients with HIV, the panel provides clinical insights on treatment selection, focusing on long-acting agents.

The panel discusses strategies to predict patients who will have poor adherence to their HIV medications and how to select the best treatment options for them.

Experts on HIV provide clinical insights on testing for drug resistance prior to treatment and approaching the topic of resistance with patients.

Paul E. Sax, MD, and Sorana Segal-Maurer, MD, discuss treatment resistance in HIV and how it has changed over the years.

The panel discusses the importance of starting HIV treatment early after diagnosis and offers advice to clinical providers.

Experts on the treatment of HIV discuss how they talk with their patients about adverse effects associated with HIV regimens.

The panel offers expert perspectives on key factors that inform treatment decisions for patients with HIV.

Focusing on the evolving treatment paradigms for HIV, the panel reviews guideline recommendations for initial therapy and discusses education practices for newly diagnosed patients.

A panel of experts on HIV open the discussion with a conversation about the role of the primary care provider and advanced practice provider in treating patients with HIV.

Co-infections of HBV and HIV often lead to an increased risk of overall mortality.

The pandemic had an immediate effect on patient care, and in pivoting to adapt to the quarantine, some changes may have created potentially permanent ways to deliver health care.

In this 9-part series, we explore how the COVID-19 pandemic may permanently change health care, treatment, and research in the future.

Cabotegravir’s FDA breakthrough designation along with adaptive strategies being deployed are the biggest stories in HIV prevention this year.

Living longer because of antiretroviral therapy (ART), people with HIV (PWH) need to be counseled for age-related medical issues, and may also be eligible for newer ART. However, social determinants, stigma about the virus, and continuum of care issues remain challenges to many within the PWH population.

Our annual series is touching on the stories in medicine that occurred during this unforgettable time.

HIV care may help enable better treatment for HCV infectious.

David Ho, MD, likens and contrasts the pandemic to 3 other viral outbreaks and their respective responses.

A famed virologist weighs in on the country's earliest shortcomings—and how they can still be resolved today.

A majority of those who fall under the criteria for recommended HIV testing has not once received such testing.

The ID-Cap System represents the only ingestible event marker able to transmit digital data within the body to an external receiver without direct skin contact.

The FDA approves Descovy to reduce the risk of HIV infection through sex.

HIV patients will be allowed to switch to doravirine or doravirine/lamivudine/tenofovir disoproxil fumarate if they are virally suppressed with no prior history of treatment failure.

A study from the University of California San Francisco found that patients with HIV were at an 80% increased risk of suffering from atrial fibrillation.

A randomized trial compared cash incentives, peer support, and usual care for increasing rate of HCV treatment among HCV/HIV infected people who use drugs.

People experiencing homelessness were more likely to follow-up on referrals from an ophthalmology clinic if they had finished high school or had a primary care provider.

Steatosis was found more often with HCV monoinfection than with HCV/HIV and more commonly detected with imaging than with biopsy.

After initiating treatment with Symtuza within 2 weeks of HIV diagnosis, 84% of patients achieved undetectable viral loads at 48 weeks.